Q-omics provides the consensus-scored PLCXD2 profile across patient tissues and cancer cell-line models. PLCXD2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PLCXD2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PLCXD2 RNA expression shows 17,821 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where PLCXD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCXD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCXD2 survival associations across molecular data types. PLCXD2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCXD2 RNA expression–survival associations across cancer types. High PLCXD2 expression shows unfavorable associations in PCPG, but favorable associations in SKCM, BLCA, LGG, SCLC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PLCXD2 RNA expression.
This table summarizes PLCXD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLCXD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCXD2 shows lower tumor expression in KIRC, KICH, LUAD, KIRP and THCA and higher tumor expression in HNSC. The KIRC box plot shows higher PLCXD2 RNA expression in normal versus tumor tissue (log2 FC = −1.657, t-test p < 0.001).
This table shows molecular features associated with PLCXD2 in patient tissues and cancer cell lines. In patient samples, PLCXD2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCXD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
